Author:  Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...